「68Ga」Ga-DOTA-Siglec-9 PET/CT 在新诊断巨细胞动脉炎中:一种炎症特异性、治疗反应性分子影像生物标志物
该概念验证研究纳入8例新诊断GCA、8例复发患者及8例对照,评估靶向VAP-1的「68Ga」Ga-DOTA-Siglec-9 PET/CT。结果显示示踪剂摄取与超声颞下动脉内膜中层厚度正相关,且随泼尼松暴露而降低;sVAP-1在新诊断GCA中低于复发患者和对照,MMP2/MMP3与血管摄取负相关。提示该PET/CT可检测GCA血管炎症并反映治疗反应。
要点
- 「68Ga」Ga-DOTA-Siglec-9 PET/CT可检测新诊断GCA的血管炎症。
- 泼尼松暴露与血管示踪剂摄取呈负相关,提示治疗反应性。
- sVAP-1降低及MMP2/MMP3与摄取负相关支持VAP-1/MMP轴机制。
核心结论
- 「68Ga」Ga-DOTA-Siglec-9 PET/CT可检测GCA血管炎症,并随泼尼松暴露而减弱。
- sVAP-1水平降低及MMP2/MMP3与示踪剂摄取的负相关支持VAP-1/MMP轴参与成像信号。
- 该PET/CT有望成为GCA的潜在分子影像生物标志物。
研究设计与样本
- 概念验证研究,纳入8例新诊断GCA患者、8例复发患者及8例对照。
- 新诊断GCA患者接受「68Ga」Ga-DOTA-Siglec-9 PET/CT和血管超声检查。
主要发现
- 超声评估的锁骨下动脉内膜中层厚度与示踪剂摄取呈正相关(r=0.67,p=0.035)。
- 泼尼松暴露与多个血管区域的摄取呈负相关(SUVmean r=-0.51,p=0.043;SUVmax r=-0.62,p=0.010)。
- sVAP-1在新诊断GCA中低于复发患者(p=0.0145)和对照(p=0.0446)。
- sVAP-1与MMP2负相关(r=-0.56,p=0.037),与MMP9负相关(r=-0.47,p=0.089)。
- MMP2和MMP3与血管摄取负相关(如主动脉弓:r=-0.59,p=0.027)。
临床怎么用
- 对于新诊断GCA,可考虑「68Ga」Ga-DOTA-Siglec-9 PET/CT评估血管炎症活动性。
- 解读PET/CT摄取时需考虑泼尼松暴露对信号衰减的影响。
- sVAP-1及MMP2/MMP3或可作为与影像信号相关的辅助生物标志物。
局限性
- 本研究为概念验证性首次人体研究,样本量小(新诊断GCA 8例)。
- 研究未报告诊断准确性指标如敏感性和特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Assessing disease activity in giant cell arteritis (GCA) remains challenging, as existing clinical, laboratory and imaging biomarkers lack specificity. This proof-of-concept study explored the diagnostic potential of vascular adhesion protein-1 (VAP-1) targeting [68Ga]Ga-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) DOTA-sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) positron emission tomography-CT (PET/CT) as an inflammation-specific molecular imaging biomarker in newly diagnosed and relapsing GCA. METHODS: Patients with newly diagnosed GCA underwent [68Ga]Ga-DOTA-Siglec-9 PET/CT and vascular ultrasound. Tracer uptake (SUVmean/SUVmax) was quantified in aortic, supra-aortic and extravascular (shoulder/hip) regions and compared with relapsing patients. Levels of soluble VAP-1 (sVAP-1) and matrix metalloproteinase (MMP)2/MMP3/MMP9 were measured in patients and controls as potential biomarkers related to vascular inflammation. RESULTS: Eight patients with newly diagnosed GCA were compared with eight relapsing patients, alongside eight controls. Imaging revealed a positive association between ultrasound-assessed subclavian artery intima-media thickness and tracer uptake (r=0.67, p=0.035). Prednisolone exposure was inversely associated with vascular uptake across various vascular regions, with SUVmean showing a stronger overall negative association than SUVmax (SUVmean r=-0.51, p=0.043; SUVmax r=-0.62, p=0.010). Levels of sVAP-1 were reduced in newly diagnosed GCA compared with relapsing patients (p=0.0145) and controls (p=0.0446), and inversely associated with MMP2 (r=-0.56, p=0.037) and MMP9 (r=-0.47, p=0.089). Notably, MMP2 and MMP3 were negatively associated with vascular uptake (eg, aortic arch: r=-0.59, p=0.027). CONCLUSIONS: This first-in-human study demonstrates that [68Ga]Ga-DOTA-Siglec-9 PET/CT detects vascular inflammation in GCA and shows attenuation with prednisolone exposure. Reduced sVAP-1 levels and inverse associations between MMP2/MMP3 and tracer uptake support a functional VAP-1/MMP axis underlying the imaging signal. Our findings further position [68Ga]Ga-DOTA-Siglec-9 PET/CT as a promising potential molecular imaging biomarker in GCA.
引用
- Petzinna SM, Küppers J, Schemmer B, et al. [68Ga]Ga-DOTA-Siglec-9 PET/CT in newly diagnosed giant cell arteritis: an inflammation-specific, treatment-responsive molecular imaging biomarker. RMD Open. 2026. PMID: 42276732. doi:10.1136/rmdopen-2025-006633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。